ERBB2 and breast carcinoma: Noteworthily, for selected patients with HER2-positive breast cancer, such as low-risk patients or older patients with cardiovascular or other comorbidities, adjuvant anti-HER2 therapy may reasonably be discontinued after 6 months instead of 12 months of treatment according to ESMO recommendations during the COVID-19 pandemic [10].